| Title |
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, September 2011
|
| DOI | 10.1007/s00262-011-1100-9 |
| Pubmed ID | |
| Authors |
Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen Visus, Albert B. DeLeo, Judith K. Wolf, Jeffrey G. Bell, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif |
| Abstract |
Peptide antigens have been administered by different approaches as cancer vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the optimal delivery method is still debatable. In this study, we describe the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Austria | 1 | 2% |
| Unknown | 63 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 23% |
| Researcher | 12 | 19% |
| Student > Bachelor | 6 | 9% |
| Student > Master | 4 | 6% |
| Other | 3 | 5% |
| Other | 6 | 9% |
| Unknown | 18 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 27% |
| Agricultural and Biological Sciences | 7 | 11% |
| Biochemistry, Genetics and Molecular Biology | 6 | 9% |
| Immunology and Microbiology | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 8 | 13% |
| Unknown | 21 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2020.
All research outputs
#6,906,939
of 22,651,245 outputs
Outputs from Cancer Immunology, Immunotherapy
#949
of 2,882 outputs
Outputs of similar age
#40,698
of 130,159 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#16
of 40 outputs
Altmetric has tracked 22,651,245 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,882 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 130,159 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.